Premier Alternatives

Tessera Therapeutics

Cambridge, MA · Founded 2018 · Privately Held (backing)

Developer of a gene writing technology designed to make permanent small and large alterations to the human genome. Tessera Therapeutics is based in Cambridge, MA and was founded in 2018. Its last reported valuation was $650 million in Dec 2024. It has raised $630 million.

Last reported valuation
$650.0M
Oct 2026
Priced at
—
Total raised
$630.0M
Last round
—

Tessera Therapeutics key facts

as of Oct 2026
  • Developer of a gene writing technology designed to make permanent small and large alterations to the human genome.
  • Tessera Therapeutics is valued at approximately $650.0M as of Oct 2026 (last reported valuation).
  • It has raised $630.0M; the latest was Later Stage VC in Dec 2025.
  • Notable investors include SoftBank Investment Advisers, University of California, Gates Foundation, EDBI, Qatar Investment Authority — 29 tracked in total.
  • Status: Privately Held (backing).
Last reported valuation
LOW confidence
$650.0M

Tessera Therapeutics's last reported valuation, Dec 2024. Nothing priced has surfaced since.

set by last reported valuationas of Oct 2026question about this number?
Free account
More of Tessera Therapeutics with a free account
  • ·The complete investor list: 29 names
  • ·Watch Tessera Therapeutics: the Monday email on marks, rounds and moves
Create free account
No card required

Membership and data by Private Market View

Tessera Therapeutics funding rounds

No rounds on record

No funding rounds for Tessera Therapeutics are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.

Pro members can request priority coverage with a 48-hour turnaround.

Tessera Therapeutics valuation

Tessera Therapeutics's last reported valuation was $650 million in Dec 2024. No priced round, secondary trade or fund mark has surfaced since.

Tessera Therapeutics investors

29 investors are on record for Tessera Therapeutics, including SoftBank Investment Advisers, University of California, Gates Foundation and EDBI. By type, the record holds 11 venture capital firms and 1 growth equity firm.

About Tessera Therapeutics

Developer of a gene writing technology designed to make permanent small and large alterations to the human genome. The company's technology helps scientists and clinicians with the ability to write small and large therapeutic messages into the genome to treat diseases at their source, enabling healthcare providers to cure their patients and improve their lives.

Sector
Healthcare
HQ
Cambridge, MA, United States
Founded
2018
Employees
292
Ownership
Privately Held (backing)

Is this your company? Sign in with your work email to keep it current, or tell us what's wrong.